WithdrawnPhase 1NCT03807063
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Studying Mixed phenotype acute leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Elizabeth KrakowFred Hutch/University of Washington Cancer Consortium
- Intervention
- Rivogenlecleucel(biological)
- Eligibility
- All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI) · Bellicum Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03807063 on ClinicalTrials.govOther trials for Mixed phenotype acute leukemia
Additional recruiting or active studies for the same condition.